Details of the Drug Combinations

General Information of This Drug (ID: DMOYJFK)

Drug Name

Valrubicin DMOYJFK

Synonyms

Valstar; Valrubicin [USAN]; Valstar Preservative Free; AD 32; Antibiotic AD 32; Valstar (TN); N-Trifluoroacetyladriamycin 14-valerate; N-Trifluoroacetyldoxorubicin 14-valerate; Trifluoroacetyladriamycin-14-valerate; Valrubicin (USP/INN); N-Trifluoroacetyladriamycin-14-valerate; Adriamycin, trifluoroacetyl-, 14-valerate; [2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-[5-hydroxy-6-methyl-4-[(2,2,2-trifluoroacetyl)amino]oxan-2-yl]oxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] pentanoate; (2S-cis)-2-(1,2,3,4,6,11-Hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacenyl)-2-oxoethyl pentanoate; (2S-cis)-Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester; (8S,10S)-8-Glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-alpha-L-lyxo-hexopyranosyl)oxy)-5,12-naphthacenedione 8(sup 2)-valerate; Pentanoic acid, 2-((2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetylamino)-, alpha-L-lysohexopyranoxyl)oxy)-2-naphthacenyl)-2-oxoethyl ester

Indication

Disease Entry	ICD 11	Status	REF
Bladder cancer	2C94	Approved	[1]
In situ carcinoma	N.A.	Approved	[2]
Urinary bladder cancer	N.A.	Approved	[2]
Psoriasis vulgaris	EA90	Phase 2	[3]
------------------------------------------------------------------------------------

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

779 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
10-hydroxycamptothecin + Valrubicin	DCGUQTH	10-hydroxycamptothecin	Anaplastic large cell lymphoma (Cell Line: SR)	[4]
10-hydroxycamptothecin + Valrubicin	DCAOWUL	10-hydroxycamptothecin	Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)	[4]
10-hydroxycamptothecin + Valrubicin	DC3PF9Q	10-hydroxycamptothecin	Clear cell renal cell carcinoma (Cell Line: A498)	[4]
10-hydroxycamptothecin + Valrubicin	DCIK4TW	10-hydroxycamptothecin	Papillary renal cell carcinoma (Cell Line: ACHN)	[4]
10-hydroxycamptothecin + Valrubicin	DC9F6QD	10-hydroxycamptothecin	Adenocarcinoma (Cell Line: NCIH23)	[5]
10-hydroxycamptothecin + Valrubicin	DC3BDSK	10-hydroxycamptothecin	Adenocarcinoma (Cell Line: HCT-15)	[5]
10-hydroxycamptothecin + Valrubicin	DCBLUSP	10-hydroxycamptothecin	Amelanotic melanoma (Cell Line: M14)	[5]
10-hydroxycamptothecin + Valrubicin	DCYD840	10-hydroxycamptothecin	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
10-hydroxycamptothecin + Valrubicin	DCVLE7W	10-hydroxycamptothecin	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
10-hydroxycamptothecin + Valrubicin	DCKJTRS	10-hydroxycamptothecin	Non-small cell lung carcinoma (Cell Line: HOP-92)	[5]
10-hydroxycamptothecin + Valrubicin	DC8R9Q2	10-hydroxycamptothecin	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
ABIRATERONE + Valrubicin	DCUPUSV	ABIRATERONE	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[4]
ABIRATERONE + Valrubicin	DCYC2Y8	ABIRATERONE	Anaplastic large cell lymphoma (Cell Line: SR)	[4]
ABIRATERONE + Valrubicin	DCIGDOY	ABIRATERONE	Plasma cell myeloma (Cell Line: RPMI-8226)	[4]
ABIRATERONE + Valrubicin	DCDC5K0	ABIRATERONE	Renal cell carcinoma (Cell Line: UO-31)	[4]
ABIRATERONE + Valrubicin	DCUDYJ7	ABIRATERONE	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[6]
ABIRATERONE + Valrubicin	DC3NJB8	ABIRATERONE	Colon adenocarcinoma (Cell Line: COLO 205)	[6]
ABIRATERONE + Valrubicin	DCSDPPQ	ABIRATERONE	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
ABIRATERONE + Valrubicin	DCFECD2	ABIRATERONE	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
ABIRATERONE + Valrubicin	DCS4PZB	ABIRATERONE	Adenocarcinoma (Cell Line: HCT-15)	[5]
ABIRATERONE + Valrubicin	DC5C4QB	ABIRATERONE	Cutaneous melanoma (Cell Line: SK-MEL-28)	[5]
ABIRATERONE + Valrubicin	DCJFLO7	ABIRATERONE	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[5]
ABIRATERONE + Valrubicin	DC9KBDJ	ABIRATERONE	Malignant melanoma (Cell Line: LOX IMVI)	[5]
ABIRATERONE + Valrubicin	DCUZ63L	ABIRATERONE	Melanoma (Cell Line: SK-MEL-2)	[5]
Amonafide + Valrubicin	DCA7UV3	Amonafide	Adenocarcinoma (Cell Line: NCIH23)	[4]
Amonafide + Valrubicin	DCPO364	Amonafide	Adenocarcinoma (Cell Line: HCT116)	[4]
Amonafide + Valrubicin	DCOF0C0	Amonafide	Adenocarcinoma (Cell Line: HCT-15)	[4]
Amonafide + Valrubicin	DC0ANMH	Amonafide	Amelanotic melanoma (Cell Line: M14)	[4]
Amonafide + Valrubicin	DCM8V7Z	Amonafide	Glioma (Cell Line: SF-268)	[4]
Amonafide + Valrubicin	DCP9CX2	Amonafide	Lung adenocarcinoma (Cell Line: HOP-62)	[4]
Anastrozole + Valrubicin	DCR9XFM	Anastrozole	Adenocarcinoma (Cell Line: HT29)	[4]
Anastrozole + Valrubicin	DC60X52	Anastrozole	Adenocarcinoma (Cell Line: HCC-2998)	[4]
Anastrozole + Valrubicin	DC6LPXE	Anastrozole	Adenocarcinoma (Cell Line: HCT-15)	[4]
Anastrozole + Valrubicin	DC604E6	Anastrozole	Amelanotic melanoma (Cell Line: M14)	[4]
Anastrozole + Valrubicin	DCX806B	Anastrozole	Glioblastoma (Cell Line: SNB-75)	[4]
Anastrozole + Valrubicin	DCIYL3M	Anastrozole	High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)	[4]
Anastrozole + Valrubicin	DC2L1WV	Anastrozole	Melanoma (Cell Line: UACC-257)	[4]
Anastrozole + Valrubicin	DCV02YK	Anastrozole	Melanoma (Cell Line: SK-MEL-2)	[4]
Anastrozole + Valrubicin	DC6D41S	Anastrozole	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[4]
Anastrozole + Valrubicin	DC54G2J	Anastrozole	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
Anastrozole + Valrubicin	DCFYXDI	Anastrozole	Colon carcinoma (Cell Line: KM12)	[6]
Anastrozole + Valrubicin	DCWCHDV	Anastrozole	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Arfolitixorin + Valrubicin	DCJTB36	Arfolitixorin	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[4]
Azacitidine + Valrubicin	DCBDA4U	Azacitidine	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[4]
Azacitidine + Valrubicin	DCEH6DW	Azacitidine	Glioblastoma (Cell Line: SNB-75)	[4]
Azacitidine + Valrubicin	DC600PR	Azacitidine	Lung adenocarcinoma (Cell Line: HOP-62)	[4]
Azacitidine + Valrubicin	DC67I93	Azacitidine	Non-small cell lung carcinoma (Cell Line: HOP-92)	[4]
BIO-300 + Valrubicin	DC302LL	BIO-300	Adenocarcinoma (Cell Line: HCT116)	[5]
Bleomycin + Valrubicin	DCMQPMV	Bleomycin	Astrocytoma (Cell Line: U251)	[4]
Bleomycin + Valrubicin	DCP50KX	Bleomycin	Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)	[4]
Bleomycin + Valrubicin	DCQIE00	Bleomycin	Chronic myelogenous leukemia (Cell Line: K-562)	[4]
Bleomycin + Valrubicin	DCFYP01	Bleomycin	Glioma (Cell Line: SF-295)	[4]
Bleomycin + Valrubicin	DCK5S1W	Bleomycin	Renal cell carcinoma (Cell Line: UO-31)	[4]
Bleomycin + Valrubicin	DC72XKQ	Bleomycin	Colon adenocarcinoma (Cell Line: COLO 205)	[6]
Bleomycin + Valrubicin	DCFZFSK	Bleomycin	Adenocarcinoma (Cell Line: NCIH23)	[5]
Bleomycin + Valrubicin	DCKEXHT	Bleomycin	Adenocarcinoma (Cell Line: SW-620)	[5]
Bleomycin + Valrubicin	DCALUK5	Bleomycin	Cutaneous melanoma (Cell Line: SK-MEL-28)	[5]
Bleomycin + Valrubicin	DCE872L	Bleomycin	Cutaneous melanoma (Cell Line: SK-MEL-5)	[5]
Bleomycin + Valrubicin	DC3LASI	Bleomycin	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[5]
Bleomycin + Valrubicin	DC8296C	Bleomycin	Malignant melanoma (Cell Line: UACC62)	[5]
Bleomycin + Valrubicin	DCBOV7A	Bleomycin	Melanoma (Cell Line: UACC-257)	[5]
Bleomycin + Valrubicin	DCR7ZOX	Bleomycin	Melanoma (Cell Line: MALME-3M)	[5]
Bleomycin + Valrubicin	DCX23MP	Bleomycin	Melanoma (Cell Line: SK-MEL-2)	[5]
Cabazitaxel + Valrubicin	DCNA33S	Cabazitaxel	Adenocarcinoma (Cell Line: HT29)	[4]
Cabazitaxel + Valrubicin	DCBEPLK	Cabazitaxel	Anaplastic large cell lymphoma (Cell Line: SR)	[4]
Cabazitaxel + Valrubicin	DCEMB0C	Cabazitaxel	Glioma (Cell Line: SF-539)	[4]
Cabazitaxel + Valrubicin	DCMI9BV	Cabazitaxel	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)	[4]
Cabazitaxel + Valrubicin	DCC646R	Cabazitaxel	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
Cabazitaxel + Valrubicin	DCOL9W3	Cabazitaxel	Lung adenocarcinoma (Cell Line: NCI-H522)	[4]
Cabazitaxel + Valrubicin	DCY9GT6	Cabazitaxel	Malignant melanoma (Cell Line: UACC62)	[4]
Cabazitaxel + Valrubicin	DCW3PP9	Cabazitaxel	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[4]
Cabazitaxel + Valrubicin	DCLSBE0	Cabazitaxel	Non-small cell lung carcinoma (Cell Line: HOP-92)	[4]
Cabazitaxel + Valrubicin	DCO3M3B	Cabazitaxel	Papillary renal cell carcinoma (Cell Line: ACHN)	[4]
Cabazitaxel + Valrubicin	DCETQD7	Cabazitaxel	Renal cell carcinoma (Cell Line: UO-31)	[4]
Cabazitaxel + Valrubicin	DCW1QAY	Cabazitaxel	Renal cell carcinoma (Cell Line: SN12C)	[4]
Cabazitaxel + Valrubicin	DC5CXAR	Cabazitaxel	Colon adenocarcinoma (Cell Line: COLO 205)	[6]
Cabazitaxel + Valrubicin	DC5PPI8	Cabazitaxel	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Crizotinib + Valrubicin	DC20SCT	Crizotinib	Adenocarcinoma (Cell Line: DU-145)	[4]
Crizotinib + Valrubicin	DC8IXZO	Crizotinib	Adenocarcinoma (Cell Line: HCT116)	[4]
Crizotinib + Valrubicin	DC666Q7	Crizotinib	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[4]
Crizotinib + Valrubicin	DC6PW5E	Crizotinib	Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)	[4]
Crizotinib + Valrubicin	DC9BP4U	Crizotinib	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[4]
Crizotinib + Valrubicin	DCAD8EQ	Crizotinib	Large cell lung carcinoma (Cell Line: NCI-H460)	[4]
Crizotinib + Valrubicin	DCJDSW2	Crizotinib	Lung adenocarcinoma (Cell Line: HOP-62)	[4]
Crizotinib + Valrubicin	DCVHG1F	Crizotinib	Melanoma (Cell Line: SK-MEL-2)	[4]
Crizotinib + Valrubicin	DCG86DP	Crizotinib	Melanoma (Cell Line: MALME-3M)	[4]
Crizotinib + Valrubicin	DC7S6FN	Crizotinib	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
Crizotinib + Valrubicin	DC6440O	Crizotinib	Plasma cell myeloma (Cell Line: RPMI-8226)	[4]
Crizotinib + Valrubicin	DCGPB5U	Crizotinib	Carcinoma (Cell Line: MCF7)	[6]
Dacarbazine + Valrubicin	DCA79GG	Dacarbazine	Adenocarcinoma (Cell Line: SW-620)	[4]
Dacarbazine + Valrubicin	DCRYZMN	Dacarbazine	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[4]
Dacarbazine + Valrubicin	DCV88K1	Dacarbazine	Amelanotic melanoma (Cell Line: MDA-MB-435)	[4]
Dacarbazine + Valrubicin	DC9VSKP	Dacarbazine	Chronic myelogenous leukemia (Cell Line: K-562)	[4]
Dacarbazine + Valrubicin	DCCODSJ	Dacarbazine	Clear cell renal cell carcinoma (Cell Line: 786-0)	[4]
Dacarbazine + Valrubicin	DCRIEA7	Dacarbazine	Melanoma (Cell Line: UACC-257)	[4]
Dacarbazine + Valrubicin	DC2S5ZO	Dacarbazine	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
Dactinomycin + Valrubicin	DC23BK7	Dactinomycin	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[6]
Dactinomycin + Valrubicin	DCUA2AU	Dactinomycin	Carcinoma (Cell Line: RXF 393)	[6]
Dactinomycin + Valrubicin	DCVQPCQ	Dactinomycin	Carcinoma (Cell Line: MCF7)	[6]
Dactinomycin + Valrubicin	DCUHEVT	Dactinomycin	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Dactinomycin + Valrubicin	DC27LT6	Dactinomycin	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
Dactinomycin + Valrubicin	DC1Z9H1	Dactinomycin	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Dactinomycin + Valrubicin	DCD1SJ4	Dactinomycin	Adenocarcinoma (Cell Line: DU-145)	[5]
Dactinomycin + Valrubicin	DCIW72W	Dactinomycin	Adenocarcinoma (Cell Line: OVCAR3)	[5]
Dactinomycin + Valrubicin	DC7E5ZW	Dactinomycin	Adenocarcinoma (Cell Line: NCIH23)	[5]
Dactinomycin + Valrubicin	DCXRYUQ	Dactinomycin	Adenocarcinoma (Cell Line: A549)	[5]
Dactinomycin + Valrubicin	DCO4Y07	Dactinomycin	Adenocarcinoma (Cell Line: SW-620)	[5]
Dactinomycin + Valrubicin	DC9TQI6	Dactinomycin	Adenocarcinoma (Cell Line: HCC-2998)	[5]
Dactinomycin + Valrubicin	DCP4CH0	Dactinomycin	Adenocarcinoma (Cell Line: HCT-15)	[5]
Dactinomycin + Valrubicin	DCMTX67	Dactinomycin	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[5]
Dactinomycin + Valrubicin	DC636KQ	Dactinomycin	Amelanotic melanoma (Cell Line: M14)	[5]
Dactinomycin + Valrubicin	DCTPRSV	Dactinomycin	Anaplastic large cell lymphoma (Cell Line: SR)	[5]
Dactinomycin + Valrubicin	DC5OQDH	Dactinomycin	Astrocytoma (Cell Line: U251)	[5]
Dactinomycin + Valrubicin	DC9YND8	Dactinomycin	Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)	[5]
Dactinomycin + Valrubicin	DCSSN98	Dactinomycin	Chronic myelogenous leukemia (Cell Line: K-562)	[5]
Dactinomycin + Valrubicin	DCU46RB	Dactinomycin	Clear cell renal cell carcinoma (Cell Line: A498)	[5]
Dactinomycin + Valrubicin	DCDHWLF	Dactinomycin	Clear cell renal cell carcinoma (Cell Line: 786-0)	[5]
Dactinomycin + Valrubicin	DCF63JA	Dactinomycin	Clear cell renal cell carcinoma (Cell Line: CAKI-1)	[5]
Dactinomycin + Valrubicin	DCFM8Y5	Dactinomycin	Cutaneous melanoma (Cell Line: SK-MEL-5)	[5]
Dactinomycin + Valrubicin	DCGSZ8Q	Dactinomycin	Cutaneous melanoma (Cell Line: SK-MEL-28)	[5]
Dactinomycin + Valrubicin	DCJB0GJ	Dactinomycin	Glioblastoma (Cell Line: SNB-75)	[5]
Dactinomycin + Valrubicin	DCF40PD	Dactinomycin	Glioma (Cell Line: SF-539)	[5]
Dactinomycin + Valrubicin	DCZSDRF	Dactinomycin	Glioma (Cell Line: SF-268)	[5]
Dactinomycin + Valrubicin	DC5O2YU	Dactinomycin	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[5]
Dactinomycin + Valrubicin	DC5SNN2	Dactinomycin	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[5]
Dactinomycin + Valrubicin	DCJONMQ	Dactinomycin	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)	[5]
Dactinomycin + Valrubicin	DCE1CM8	Dactinomycin	High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)	[5]
Dactinomycin + Valrubicin	DCNKLYM	Dactinomycin	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[5]
Dactinomycin + Valrubicin	DCJINAR	Dactinomycin	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Dactinomycin + Valrubicin	DC1JWAE	Dactinomycin	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
Dactinomycin + Valrubicin	DCIHFP8	Dactinomycin	Lung adenocarcinoma (Cell Line: NCI-H522)	[5]
Dactinomycin + Valrubicin	DCF7ZPW	Dactinomycin	Malignant melanoma (Cell Line: UACC62)	[5]
Dactinomycin + Valrubicin	DCYSSA1	Dactinomycin	Melanoma (Cell Line: UACC-257)	[5]
Dactinomycin + Valrubicin	DCR9MB7	Dactinomycin	Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)	[5]
Dactinomycin + Valrubicin	DCMHWIK	Dactinomycin	Non-small cell lung carcinoma (Cell Line: HOP-92)	[5]
Dactinomycin + Valrubicin	DC9QJBQ	Dactinomycin	Papillary renal cell carcinoma (Cell Line: ACHN)	[5]
Dactinomycin + Valrubicin	DCK2514	Dactinomycin	Plasma cell myeloma (Cell Line: RPMI-8226)	[5]
Dactinomycin + Valrubicin	DCX53P5	Dactinomycin	Prostate carcinoma (Cell Line: PC-3)	[5]
Dactinomycin + Valrubicin	DC8PW2W	Dactinomycin	Renal cell carcinoma (Cell Line: UO-31)	[5]
Dactinomycin + Valrubicin	DC89F8U	Dactinomycin	Renal cell carcinoma (Cell Line: SN12C)	[5]
Dasatinib + Valrubicin	DC8J3DO	Dasatinib	Adenocarcinoma (Cell Line: HCT116)	[4]
Dasatinib + Valrubicin	DCBO70A	Dasatinib	Adenocarcinoma (Cell Line: HT29)	[4]
Dasatinib + Valrubicin	DCFDTNK	Dasatinib	Adenocarcinoma (Cell Line: HCT-15)	[4]
Dasatinib + Valrubicin	DCHFNH6	Dasatinib	Amelanotic melanoma (Cell Line: M14)	[4]
Dasatinib + Valrubicin	DCR63ZN	Dasatinib	Astrocytoma (Cell Line: U251)	[4]
Dasatinib + Valrubicin	DCREQZT	Dasatinib	Astrocytoma (Cell Line: SNB-19)	[4]
Dasatinib + Valrubicin	DCN2OIS	Dasatinib	Chronic myelogenous leukemia (Cell Line: K-562)	[4]
Dasatinib + Valrubicin	DCRAUMN	Dasatinib	Clear cell renal cell carcinoma (Cell Line: A498)	[4]
Dasatinib + Valrubicin	DCWEKXL	Dasatinib	Glioma (Cell Line: SF-539)	[4]
Dasatinib + Valrubicin	DCF2D26	Dasatinib	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[4]
Dasatinib + Valrubicin	DCZOGVH	Dasatinib	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)	[4]
Dasatinib + Valrubicin	DC41ISQ	Dasatinib	High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)	[4]
Dasatinib + Valrubicin	DCM7M63	Dasatinib	Lung adenocarcinoma (Cell Line: HOP-62)	[4]
Dasatinib + Valrubicin	DCO0RKG	Dasatinib	Malignant melanoma (Cell Line: UACC62)	[4]
Dasatinib + Valrubicin	DCZ6GRM	Dasatinib	Non-small cell lung carcinoma (Cell Line: HOP-92)	[4]
Dasatinib + Valrubicin	DCPJWME	Dasatinib	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
Dasatinib + Valrubicin	DCFPLL0	Dasatinib	Papillary renal cell carcinoma (Cell Line: ACHN)	[4]
Dasatinib + Valrubicin	DC44Y0O	Dasatinib	Pleural epithelioid mesothelioma (Cell Line: NCI-H226)	[4]
Dasatinib + Valrubicin	DCKG5OU	Dasatinib	Prostate carcinoma (Cell Line: PC-3)	[4]
Dasatinib + Valrubicin	DC1W56U	Dasatinib	Renal cell carcinoma (Cell Line: SN12C)	[4]
Dasatinib + Valrubicin	DCFNP8E	Dasatinib	Carcinoma (Cell Line: MCF7)	[6]
Dasatinib + Valrubicin	DC5M2M6	Dasatinib	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Dexrazoxane + Valrubicin	DCF08EK	Dexrazoxane	Colon adenocarcinoma (Cell Line: COLO 205)	[6]
Digitoxin + Valrubicin	DCRBCI4	Digitoxin	Amelanotic melanoma (Cell Line: M14)	[4]
Digitoxin + Valrubicin	DCP8YL9	Digitoxin	Glioma (Cell Line: SF-295)	[4]
Digitoxin + Valrubicin	DC9HF1Z	Digitoxin	Glioma (Cell Line: SF-268)	[4]
Digitoxin + Valrubicin	DCT3VKB	Digitoxin	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[4]
Epirubicin + Valrubicin	DCL8ZOM	Epirubicin	Anaplastic large cell lymphoma (Cell Line: SR)	[4]
Epirubicin + Valrubicin	DC5YUHK	Epirubicin	Plasma cell myeloma (Cell Line: RPMI-8226)	[4]
Epirubicin + Valrubicin	DC0V13Q	Epirubicin	Renal cell carcinoma (Cell Line: UO-31)	[4]
Epirubicin + Valrubicin	DC6CFTQ	Epirubicin	Carcinoma (Cell Line: MCF7)	[6]
Epirubicin + Valrubicin	DC88HXA	Epirubicin	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Epirubicin + Valrubicin	DCK65DA	Epirubicin	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
Epirubicin + Valrubicin	DC927ZQ	Epirubicin	Adenocarcinoma (Cell Line: NCIH23)	[5]
Epirubicin + Valrubicin	DCM7XTC	Epirubicin	Adenocarcinoma (Cell Line: HT29)	[5]
Epirubicin + Valrubicin	DCCJ93M	Epirubicin	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
Epirubicin + Valrubicin	DCJU8PU	Epirubicin	Cutaneous melanoma (Cell Line: SK-MEL-28)	[5]
Epirubicin + Valrubicin	DCOWB0E	Epirubicin	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[5]
Epirubicin + Valrubicin	DCGP8SW	Epirubicin	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[5]
Epirubicin + Valrubicin	DC79HZD	Epirubicin	Melanoma (Cell Line: UACC-257)	[5]
Epirubicin + Valrubicin	DCNYBQ9	Epirubicin	Melanoma (Cell Line: MALME-3M)	[5]
Epirubicin + Valrubicin	DCZDZG2	Epirubicin	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Estramustine + Valrubicin	DCET2N6	Estramustine	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[4]
Estramustine + Valrubicin	DC7R4IV	Estramustine	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[4]
Estramustine + Valrubicin	DCWA0K8	Estramustine	Anaplastic large cell lymphoma (Cell Line: SR)	[4]
Estramustine + Valrubicin	DCRRNX6	Estramustine	Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)	[4]
Fludarabine + Valrubicin	DC3RKU4	Fludarabine	Clear cell renal cell carcinoma (Cell Line: A498)	[4]
Fludarabine + Valrubicin	DC7VBXK	Fludarabine	Glioblastoma (Cell Line: SNB-75)	[4]
Fludarabine + Valrubicin	DCKFZK4	Fludarabine	Adenocarcinoma (Cell Line: OVCAR3)	[5]
Fludarabine + Valrubicin	DCL0M5Q	Fludarabine	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[5]
Gefitinib + Valrubicin	DCU6RG3	Gefitinib	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[4]
Imatinib + Valrubicin	DCPWWQS	Imatinib	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[4]
Imatinib + Valrubicin	DCFWURP	Imatinib	Renal cell carcinoma (Cell Line: UO-31)	[4]
Indazole derivative 5 + Valrubicin	DCCEUHI	Indazole derivative 5	Anaplastic large cell lymphoma (Cell Line: SR)	[4]
Indazole derivative 5 + Valrubicin	DCOPYPK	Indazole derivative 5	Plasma cell myeloma (Cell Line: RPMI-8226)	[4]
Indazole derivative 5 + Valrubicin	DCJEEJ2	Indazole derivative 5	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Indazole derivative 5 + Valrubicin	DCPDFZD	Indazole derivative 5	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Indazole derivative 5 + Valrubicin	DCYVMRB	Indazole derivative 5	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
Indazole derivative 5 + Valrubicin	DCKID3R	Indazole derivative 5	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
Indazole derivative 5 + Valrubicin	DCZLM7U	Indazole derivative 5	Cutaneous melanoma (Cell Line: SK-MEL-28)	[5]
Indazole derivative 5 + Valrubicin	DCVMIGK	Indazole derivative 5	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
Indazole derivative 5 + Valrubicin	DCNWCV0	Indazole derivative 5	Melanoma (Cell Line: SK-MEL-2)	[5]
Indazole derivative 5 + Valrubicin	DCFJY11	Indazole derivative 5	Melanoma (Cell Line: MALME-3M)	[5]
Indazole derivative 5 + Valrubicin	DC96N5K	Indazole derivative 5	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
JNK-IN-8 + Valrubicin	DCXIS4L	JNK-IN-8	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[4]
JNK-IN-8 + Valrubicin	DC9GXZF	JNK-IN-8	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[4]
JNK-IN-8 + Valrubicin	DCSNOA3	JNK-IN-8	Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)	[4]
JNK-IN-8 + Valrubicin	DCMU4YJ	JNK-IN-8	Renal cell carcinoma (Cell Line: SN12C)	[4]
JNK-IN-8 + Valrubicin	DC2RNEK	JNK-IN-8	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Lapatinib + Valrubicin	DCYTO7X	Lapatinib	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[5]
Lapatinib + Valrubicin	DCSLPLM	Lapatinib	Amelanotic melanoma (Cell Line: M14)	[5]
Lapatinib + Valrubicin	DCCZY1U	Lapatinib	Anaplastic large cell lymphoma (Cell Line: SR)	[5]
Lapatinib + Valrubicin	DCP2ICM	Lapatinib	Glioma (Cell Line: SF-268)	[5]
Lapatinib + Valrubicin	DC7T0XN	Lapatinib	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[5]
Lapatinib + Valrubicin	DCAZ1XG	Lapatinib	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Lapatinib + Valrubicin	DCCYP4F	Lapatinib	Non-small cell lung carcinoma (Cell Line: HOP-92)	[5]
Lenalidomide + Valrubicin	DCQXA45	Lenalidomide	Adenocarcinoma (Cell Line: HCC-2998)	[5]
Letrozole + Valrubicin	DC9V811	Letrozole	Adenocarcinoma (Cell Line: OVCAR3)	[4]
Letrozole + Valrubicin	DC7ZUQD	Letrozole	Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)	[4]
Letrozole + Valrubicin	DCUXP29	Letrozole	Glioblastoma (Cell Line: SNB-75)	[4]
Letrozole + Valrubicin	DCC3Z6L	Letrozole	Renal cell carcinoma (Cell Line: UO-31)	[4]
Letrozole + Valrubicin	DCMLH89	Letrozole	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[6]
Letrozole + Valrubicin	DCDI3MI	Letrozole	Colon carcinoma (Cell Line: KM12)	[6]
Mechlorethamine + Valrubicin	DCFOFM8	Mechlorethamine	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[4]
Mechlorethamine + Valrubicin	DCDS61R	Mechlorethamine	Chronic myelogenous leukemia (Cell Line: K-562)	[4]
Mechlorethamine + Valrubicin	DC40A28	Mechlorethamine	Plasma cell myeloma (Cell Line: RPMI-8226)	[4]
Mechlorethamine + Valrubicin	DC6BDYI	Mechlorethamine	Colon adenocarcinoma (Cell Line: COLO 205)	[6]
Mechlorethamine + Valrubicin	DCCIUXH	Mechlorethamine	Colon carcinoma (Cell Line: KM12)	[6]
Mechlorethamine + Valrubicin	DCSRMLV	Mechlorethamine	Adenocarcinoma (Cell Line: SW-620)	[5]
Mechlorethamine + Valrubicin	DC221SE	Mechlorethamine	Cutaneous melanoma (Cell Line: SK-MEL-28)	[5]
Mechlorethamine + Valrubicin	DCZ0XK3	Mechlorethamine	Malignant melanoma (Cell Line: LOX IMVI)	[5]
Mechlorethamine + Valrubicin	DCO86ZO	Mechlorethamine	Melanoma (Cell Line: SK-MEL-2)	[5]
Mechlorethamine + Valrubicin	DCM81MY	Mechlorethamine	Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)	[5]
Mechlorethamine + Valrubicin	DCAMPV2	Mechlorethamine	Prostate carcinoma (Cell Line: PC-3)	[5]
Nilotinib + Valrubicin	DC6PRJQ	Nilotinib	Clear cell renal cell carcinoma (Cell Line: 786-0)	[4]
Nilotinib + Valrubicin	DC0EWQH	Nilotinib	Renal cell carcinoma (Cell Line: UO-31)	[4]
Nilotinib + Valrubicin	DC3JRIH	Nilotinib	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
Nilotinib + Valrubicin	DCJYR11	Nilotinib	Amelanotic melanoma (Cell Line: M14)	[5]
Nilotinib + Valrubicin	DC50NOO	Nilotinib	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[5]
Nilotinib + Valrubicin	DCZJQ8N	Nilotinib	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[5]
Nilotinib + Valrubicin	DCWYJR4	Nilotinib	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Nilotinib + Valrubicin	DCGAOCY	Nilotinib	Malignant melanoma (Cell Line: UACC62)	[5]
Picoplatin + Valrubicin	DCDUSIR	Picoplatin	Colon adenocarcinoma (Cell Line: COLO 205)	[6]
Plicamycin + Valrubicin	DCU67JC	Plicamycin	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[4]
Plicamycin + Valrubicin	DC1GRLT	Plicamycin	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[4]
Plicamycin + Valrubicin	DCOS4XC	Plicamycin	Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)	[4]
Plicamycin + Valrubicin	DC5ABT0	Plicamycin	Chronic myelogenous leukemia (Cell Line: K-562)	[4]
Plicamycin + Valrubicin	DCNYQJF	Plicamycin	Glioblastoma (Cell Line: SNB-75)	[4]
Plicamycin + Valrubicin	DCBJ9PH	Plicamycin	Glioma (Cell Line: SF-539)	[4]
Plicamycin + Valrubicin	DC3I9VJ	Plicamycin	Glioma (Cell Line: SF-268)	[4]
Plicamycin + Valrubicin	DC5KT1B	Plicamycin	Plasma cell myeloma (Cell Line: RPMI-8226)	[4]
Plicamycin + Valrubicin	DCQL7G7	Plicamycin	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Plicamycin + Valrubicin	DC16DQ9	Plicamycin	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
Plicamycin + Valrubicin	DCR95X5	Plicamycin	Adenocarcinoma (Cell Line: SW-620)	[5]
Plicamycin + Valrubicin	DCVQWJQ	Plicamycin	Adenocarcinoma (Cell Line: HCT116)	[5]
Plicamycin + Valrubicin	DCCPQAN	Plicamycin	Adenocarcinoma (Cell Line: HCT-15)	[5]
Plicamycin + Valrubicin	DCA3LMJ	Plicamycin	Amelanotic melanoma (Cell Line: M14)	[5]
Plicamycin + Valrubicin	DCBDBVE	Plicamycin	Cutaneous melanoma (Cell Line: SK-MEL-5)	[5]
Plicamycin + Valrubicin	DCSVIGW	Plicamycin	Cutaneous melanoma (Cell Line: SK-MEL-28)	[5]
Plicamycin + Valrubicin	DCR5EDM	Plicamycin	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[5]
Plicamycin + Valrubicin	DCV02ZH	Plicamycin	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
Plicamycin + Valrubicin	DC62ZF2	Plicamycin	Lung adenocarcinoma (Cell Line: NCI-H522)	[5]
Plicamycin + Valrubicin	DC5MYCQ	Plicamycin	Malignant melanoma (Cell Line: UACC62)	[5]
Plicamycin + Valrubicin	DCKNM6V	Plicamycin	Malignant melanoma (Cell Line: LOX IMVI)	[5]
Plicamycin + Valrubicin	DC69ARK	Plicamycin	Melanoma (Cell Line: MALME-3M)	[5]
Plicamycin + Valrubicin	DC2RBJA	Plicamycin	Melanoma (Cell Line: SK-MEL-2)	[5]
Plicamycin + Valrubicin	DCSJVDW	Plicamycin	Melanoma (Cell Line: UACC-257)	[5]
Plicamycin + Valrubicin	DCKG4T6	Plicamycin	Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)	[5]
Plicamycin + Valrubicin	DCQ1BPG	Plicamycin	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[5]
Plicamycin + Valrubicin	DC4O861	Plicamycin	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Raloxifene + Valrubicin	DCG9RGZ	Raloxifene	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[4]
Raloxifene + Valrubicin	DCXV013	Raloxifene	Anaplastic large cell lymphoma (Cell Line: SR)	[4]
Raloxifene + Valrubicin	DCPWVVP	Raloxifene	Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)	[4]
Raloxifene + Valrubicin	DCKRW8Z	Raloxifene	Glioblastoma (Cell Line: SNB-75)	[4]
Raloxifene + Valrubicin	DCBAU5T	Raloxifene	Papillary renal cell carcinoma (Cell Line: ACHN)	[4]
Raloxifene + Valrubicin	DC1I160	Raloxifene	Plasma cell myeloma (Cell Line: RPMI-8226)	[4]
Raloxifene + Valrubicin	DCJIP3U	Raloxifene	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[6]
Raloxifene + Valrubicin	DC3118Q	Raloxifene	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Raloxifene + Valrubicin	DC4U32T	Raloxifene	Adenocarcinoma (Cell Line: DU-145)	[5]
Raloxifene + Valrubicin	DCBH3W9	Raloxifene	Adenocarcinoma (Cell Line: NCIH23)	[5]
Raloxifene + Valrubicin	DCB9HVG	Raloxifene	Adenocarcinoma (Cell Line: HCT116)	[5]
Raloxifene + Valrubicin	DCTXJB4	Raloxifene	Amelanotic melanoma (Cell Line: M14)	[5]
Raloxifene + Valrubicin	DC0ZEVL	Raloxifene	Cutaneous melanoma (Cell Line: SK-MEL-28)	[5]
Raloxifene + Valrubicin	DC4I2F5	Raloxifene	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[5]
Raloxifene + Valrubicin	DCUI8I6	Raloxifene	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Raloxifene + Valrubicin	DCPCSPW	Raloxifene	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
Raloxifene + Valrubicin	DC2YD9F	Raloxifene	Malignant melanoma (Cell Line: UACC62)	[5]
Raloxifene + Valrubicin	DC0TDVV	Raloxifene	Melanoma (Cell Line: MALME-3M)	[5]
Raloxifene + Valrubicin	DCNN0YK	Raloxifene	Melanoma (Cell Line: SK-MEL-2)	[5]
Romidepsin + Valrubicin	DC4EPFT	Romidepsin	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[4]
Romidepsin + Valrubicin	DCUY1GF	Romidepsin	Anaplastic large cell lymphoma (Cell Line: SR)	[4]
Romidepsin + Valrubicin	DCYSS6E	Romidepsin	Clear cell renal cell carcinoma (Cell Line: A498)	[4]
Romidepsin + Valrubicin	DCVNXTC	Romidepsin	Clear cell renal cell carcinoma (Cell Line: 786-0)	[4]
Romidepsin + Valrubicin	DC20IEW	Romidepsin	Clear cell renal cell carcinoma (Cell Line: CAKI-1)	[4]
Romidepsin + Valrubicin	DC92CL0	Romidepsin	Papillary renal cell carcinoma (Cell Line: ACHN)	[4]
Romidepsin + Valrubicin	DCY8QRE	Romidepsin	Plasma cell myeloma (Cell Line: RPMI-8226)	[4]
Romidepsin + Valrubicin	DC3M47H	Romidepsin	Renal cell carcinoma (Cell Line: SN12C)	[4]
Romidepsin + Valrubicin	DCZXCRU	Romidepsin	Carcinoma (Cell Line: MCF7)	[6]
Romidepsin + Valrubicin	DCMBDUU	Romidepsin	Colon carcinoma (Cell Line: KM12)	[6]
Romidepsin + Valrubicin	DCNADWX	Romidepsin	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
Romidepsin + Valrubicin	DCT8H5O	Romidepsin	Adenocarcinoma (Cell Line: NCIH23)	[5]
Romidepsin + Valrubicin	DC4JSF3	Romidepsin	Adenocarcinoma (Cell Line: HCC-2998)	[5]
Romidepsin + Valrubicin	DC4BGTA	Romidepsin	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
Romidepsin + Valrubicin	DCPLV6P	Romidepsin	Amelanotic melanoma (Cell Line: M14)	[5]
Romidepsin + Valrubicin	DCH0KT7	Romidepsin	High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)	[5]
Romidepsin + Valrubicin	DCXVAQL	Romidepsin	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
Romidepsin + Valrubicin	DCNSBOI	Romidepsin	Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)	[5]
Romidepsin + Valrubicin	DCD3T2V	Romidepsin	Non-small cell lung carcinoma (Cell Line: HOP-92)	[5]
Romidepsin + Valrubicin	DCUZ4PK	Romidepsin	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Ruxolitinib + Valrubicin	DCY3FUN	Ruxolitinib	Anaplastic large cell lymphoma (Cell Line: SR)	[4]
Ruxolitinib + Valrubicin	DCF6CK5	Ruxolitinib	Plasma cell myeloma (Cell Line: RPMI-8226)	[4]
Ruxolitinib + Valrubicin	DCUTLJ1	Ruxolitinib	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Ruxolitinib + Valrubicin	DCT4SYF	Ruxolitinib	Adenocarcinoma (Cell Line: DU-145)	[5]
Ruxolitinib + Valrubicin	DCUN36F	Ruxolitinib	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
Ruxolitinib + Valrubicin	DCYAY5M	Ruxolitinib	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[5]
Ruxolitinib + Valrubicin	DC67DSC	Ruxolitinib	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Ruxolitinib + Valrubicin	DCBEKKT	Ruxolitinib	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
Ruxolitinib + Valrubicin	DCDT7J1	Ruxolitinib	Melanoma (Cell Line: SK-MEL-2)	[5]
Ruxolitinib + Valrubicin	DCLY8Q7	Ruxolitinib	Melanoma (Cell Line: MALME-3M)	[5]
Ruxolitinib + Valrubicin	DCHDEZU	Ruxolitinib	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
SCH 727965 + Valrubicin	DC3ECH3	SCH 727965	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[4]
SCH 727965 + Valrubicin	DC0CBU4	SCH 727965	Anaplastic large cell lymphoma (Cell Line: SR)	[4]
SCH 727965 + Valrubicin	DCC1JXJ	SCH 727965	Astrocytoma (Cell Line: U251)	[4]
SCH 727965 + Valrubicin	DC2Z4XG	SCH 727965	Astrocytoma (Cell Line: SNB-19)	[4]
SCH 727965 + Valrubicin	DC7IJ0V	SCH 727965	Clear cell renal cell carcinoma (Cell Line: 786-0)	[4]
SCH 727965 + Valrubicin	DCPXMZ9	SCH 727965	Clear cell renal cell carcinoma (Cell Line: A498)	[4]
SCH 727965 + Valrubicin	DC4QHED	SCH 727965	Clear cell renal cell carcinoma (Cell Line: CAKI-1)	[4]
SCH 727965 + Valrubicin	DCM1H33	SCH 727965	Glioblastoma (Cell Line: SNB-75)	[4]
SCH 727965 + Valrubicin	DCCXNR5	SCH 727965	Glioma (Cell Line: SF-539)	[4]
SCH 727965 + Valrubicin	DC74M4D	SCH 727965	Papillary renal cell carcinoma (Cell Line: ACHN)	[4]
SCH 727965 + Valrubicin	DC7AHQP	SCH 727965	Plasma cell myeloma (Cell Line: RPMI-8226)	[4]
SCH 727965 + Valrubicin	DC52B8U	SCH 727965	Renal cell carcinoma (Cell Line: SN12C)	[4]
SCH 727965 + Valrubicin	DCZSYQ0	SCH 727965	Renal cell carcinoma (Cell Line: UO-31)	[4]
SCH 727965 + Valrubicin	DCKVWFQ	SCH 727965	Carcinoma (Cell Line: RXF 393)	[6]
SCH 727965 + Valrubicin	DCTBWQQ	SCH 727965	Colon adenocarcinoma (Cell Line: COLO 205)	[6]
SCH 727965 + Valrubicin	DC6A5AC	SCH 727965	Colon carcinoma (Cell Line: KM12)	[6]
SCH 727965 + Valrubicin	DCZTHPL	SCH 727965	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
SCH 727965 + Valrubicin	DC5MKNF	SCH 727965	Adenocarcinoma (Cell Line: DU-145)	[5]
SCH 727965 + Valrubicin	DC2HNV6	SCH 727965	Adenocarcinoma (Cell Line: OVCAR3)	[5]
SCH 727965 + Valrubicin	DCKBY92	SCH 727965	Adenocarcinoma (Cell Line: NCIH23)	[5]
SCH 727965 + Valrubicin	DCYOP9S	SCH 727965	Adenocarcinoma (Cell Line: SW-620)	[5]
SCH 727965 + Valrubicin	DCW2NC9	SCH 727965	Adenocarcinoma (Cell Line: HCT-15)	[5]
SCH 727965 + Valrubicin	DCR7ES1	SCH 727965	Adenocarcinoma (Cell Line: HT29)	[5]
SCH 727965 + Valrubicin	DC6U5RO	SCH 727965	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
SCH 727965 + Valrubicin	DCDTD20	SCH 727965	Amelanotic melanoma (Cell Line: M14)	[5]
SCH 727965 + Valrubicin	DCCO3KL	SCH 727965	Cutaneous melanoma (Cell Line: SK-MEL-5)	[5]
SCH 727965 + Valrubicin	DC4B7EZ	SCH 727965	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)	[5]
SCH 727965 + Valrubicin	DCEMDPV	SCH 727965	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[5]
SCH 727965 + Valrubicin	DCXET5M	SCH 727965	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[5]
SCH 727965 + Valrubicin	DCL0QJR	SCH 727965	High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)	[5]
SCH 727965 + Valrubicin	DCJ9X6E	SCH 727965	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
SCH 727965 + Valrubicin	DCKIRZX	SCH 727965	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[5]
SCH 727965 + Valrubicin	DCRAVKK	SCH 727965	Lung adenocarcinoma (Cell Line: EKVX)	[5]
SCH 727965 + Valrubicin	DC58857	SCH 727965	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
SCH 727965 + Valrubicin	DCK864R	SCH 727965	Lung adenocarcinoma (Cell Line: NCI-H522)	[5]
SCH 727965 + Valrubicin	DCVR6RL	SCH 727965	Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)	[5]
SCH 727965 + Valrubicin	DCNGAI7	SCH 727965	Non-small cell lung carcinoma (Cell Line: HOP-92)	[5]
SCH 727965 + Valrubicin	DCI6KVJ	SCH 727965	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Sirolimus + Valrubicin	DCCVTMP	Sirolimus	Clear cell renal cell carcinoma (Cell Line: 786-0)	[4]
Sirolimus + Valrubicin	DCJO842	Sirolimus	Glioblastoma (Cell Line: SNB-75)	[4]
Sirolimus + Valrubicin	DCG520H	Sirolimus	Carcinoma (Cell Line: RXF 393)	[6]
Sirolimus + Valrubicin	DCCR4QT	Sirolimus	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Sirolimus + Valrubicin	DCE7YV4	Sirolimus	Adenocarcinoma (Cell Line: OVCAR3)	[5]
Sirolimus + Valrubicin	DCBP3RP	Sirolimus	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[5]
Sirolimus + Valrubicin	DCNMBPY	Sirolimus	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
Sirolimus + Valrubicin	DCXT7RI	Sirolimus	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Sirolimus + Valrubicin	DC0ODXH	Sirolimus	Malignant melanoma (Cell Line: UACC62)	[5]
SY-1425 + Valrubicin	DC0CDNZ	SY-1425	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[4]
SY-1425 + Valrubicin	DCBQJVD	SY-1425	Plasma cell myeloma (Cell Line: RPMI-8226)	[4]
SY-1425 + Valrubicin	DC2JDXA	SY-1425	Renal cell carcinoma (Cell Line: UO-31)	[4]
SY-1425 + Valrubicin	DCFKA4U	SY-1425	Carcinoma (Cell Line: MCF7)	[6]
SY-1425 + Valrubicin	DCCJL8D	SY-1425	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
SY-1425 + Valrubicin	DCO10C3	SY-1425	Adenocarcinoma (Cell Line: HCC-2998)	[5]
SY-1425 + Valrubicin	DC7Y7N0	SY-1425	Adenocarcinoma (Cell Line: HCT-15)	[5]
SY-1425 + Valrubicin	DCMT95V	SY-1425	Melanoma (Cell Line: MALME-3M)	[5]
Taxol + Valrubicin	DCX25X5	Taxol	Clear cell renal cell carcinoma (Cell Line: 786-0)	[4]
Taxol + Valrubicin	DCRGN3L	Taxol	Renal cell carcinoma (Cell Line: SN12C)	[4]
Taxol + Valrubicin	DCZ9XZY	Taxol	Renal cell carcinoma (Cell Line: UO-31)	[4]
Taxol + Valrubicin	DCL0P2X	Taxol	Carcinoma (Cell Line: MCF7)	[6]
Taxol + Valrubicin	DC8UHGE	Taxol	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
Taxol + Valrubicin	DCQGXPE	Taxol	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Taxol + Valrubicin	DC6PCGW	Taxol	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
Taxol + Valrubicin	DCCJNQ5	Taxol	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Thioguanine + Valrubicin	DC1MSFP	Thioguanine	Clear cell renal cell carcinoma (Cell Line: CAKI-1)	[4]
Thioguanine + Valrubicin	DC4LO9M	Thioguanine	Plasma cell myeloma (Cell Line: RPMI-8226)	[4]
Thioguanine + Valrubicin	DCCFXHU	Thioguanine	Colon adenocarcinoma (Cell Line: COLO 205)	[6]
Thioguanine + Valrubicin	DCZNRUP	Thioguanine	Adenocarcinoma (Cell Line: A549)	[5]
Topotecan + Valrubicin	DCM1JXN	Topotecan	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[5]
Topotecan + Valrubicin	DCK1YSB	Topotecan	Amelanotic melanoma (Cell Line: M14)	[5]
Topotecan + Valrubicin	DCO2L51	Topotecan	Astrocytoma (Cell Line: SNB-19)	[5]
Topotecan + Valrubicin	DC3Q6T6	Topotecan	Clear cell renal cell carcinoma (Cell Line: 786-0)	[5]
Topotecan + Valrubicin	DCOGUIX	Topotecan	Clear cell renal cell carcinoma (Cell Line: CAKI-1)	[5]
Topotecan + Valrubicin	DCNVAAT	Topotecan	Cutaneous melanoma (Cell Line: SK-MEL-28)	[5]
Topotecan + Valrubicin	DC7INYL	Topotecan	Glioma (Cell Line: SF-268)	[5]
Topotecan + Valrubicin	DCKQ60M	Topotecan	Melanoma (Cell Line: MALME-3M)	[5]
Topotecan + Valrubicin	DCPKN3I	Topotecan	Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)	[5]
Topotecan + Valrubicin	DCCZJ9E	Topotecan	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[5]
Topotecan + Valrubicin	DCGZ4UR	Topotecan	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Topotecan + Valrubicin	DCPLGVB	Topotecan	Pleural epithelioid mesothelioma (Cell Line: NCI-H226)	[5]
Topotecan + Valrubicin	DC3ERO1	Topotecan	Prostate carcinoma (Cell Line: PC-3)	[5]
Triapine + Valrubicin	DC92ZLO	Triapine	Colon carcinoma (Cell Line: KM12)	[6]
Triapine + Valrubicin	DCSZIU2	Triapine	Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)	[5]
Triapine + Valrubicin	DC8LBZ7	Triapine	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[5]
Trifluridine + Valrubicin	DCZLFMU	Trifluridine	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[5]
Trifluridine + Valrubicin	DCTHFAA	Trifluridine	Lung adenocarcinoma (Cell Line: NCI-H522)	[5]
Trifluridine + Valrubicin	DC4QXY6	Trifluridine	Melanoma (Cell Line: MALME-3M)	[5]
Valrubicin + Pentostatin	DCY5M5K	Pentostatin	Clear cell renal cell carcinoma (Cell Line: CAKI-1)	[4]
Valrubicin + Ixabepilone	DCKPWPI	Ixabepilone	Astrocytoma (Cell Line: U251)	[4]
Valrubicin + Ixabepilone	DCZDB1U	Ixabepilone	Glioma (Cell Line: SF-295)	[4]
Valrubicin + Dactinomycin	DC3WVW0	Dactinomycin	Astrocytoma (Cell Line: SNB-19)	[4]
Valrubicin + Dactinomycin	DCTHQJ4	Dactinomycin	Clear cell renal cell carcinoma (Cell Line: A498)	[4]
Valrubicin + Dactinomycin	DCXSFGU	Dactinomycin	Glioma (Cell Line: SF-268)	[4]
Valrubicin + PMID28460551-Compound-2	DCL0PD6	PMID28460551-Compound-2	Astrocytoma (Cell Line: SNB-19)	[4]
Valrubicin + PMID28460551-Compound-2	DC89CII	PMID28460551-Compound-2	Clear cell renal cell carcinoma (Cell Line: A498)	[4]
Valrubicin + PMID28460551-Compound-2	DC48Y0V	PMID28460551-Compound-2	Clear cell renal cell carcinoma (Cell Line: 786-0)	[4]
Valrubicin + PMID28460551-Compound-2	DCE6B9E	PMID28460551-Compound-2	Clear cell renal cell carcinoma (Cell Line: TK-10)	[4]
Valrubicin + PMID28460551-Compound-2	DCKVQQN	PMID28460551-Compound-2	Glioblastoma (Cell Line: SNB-75)	[4]
Valrubicin + PMID28460551-Compound-2	DCM62E8	PMID28460551-Compound-2	Glioma (Cell Line: SF-268)	[4]
Valrubicin + PMID28460551-Compound-2	DCCZXFO	PMID28460551-Compound-2	Papillary renal cell carcinoma (Cell Line: ACHN)	[4]
Valrubicin + PMID28460551-Compound-2	DC2VPZ8	PMID28460551-Compound-2	Plasma cell myeloma (Cell Line: RPMI-8226)	[4]
Valrubicin + Cyclophosphamide	DC6HGXP	Cyclophosphamide	Astrocytoma (Cell Line: U251)	[4]
Valrubicin + Panobinostat	DCJ5T07	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[4]
Valrubicin + Methotrexate	DCLAEIE	Methotrexate	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[4]
Valrubicin + Methotrexate	DC0AXBY	Methotrexate	Astrocytoma (Cell Line: U251)	[4]
Valrubicin + Methotrexate	DCDEUSY	Methotrexate	Clear cell renal cell carcinoma (Cell Line: A498)	[4]
Valrubicin + Isoniazid	DCHLG0S	Isoniazid	Clear cell renal cell carcinoma (Cell Line: A498)	[4]
Valrubicin + Isoniazid	DCA743E	Isoniazid	Glioma (Cell Line: SF-295)	[4]
Valrubicin + Arsenic trioxide	DC7UX2B	Arsenic trioxide	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[4]
Valrubicin + Arsenic trioxide	DCBJ7DW	Arsenic trioxide	Anaplastic large cell lymphoma (Cell Line: SR)	[4]
Valrubicin + Arsenic trioxide	DCVS9DD	Arsenic trioxide	Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)	[4]
Valrubicin + Arsenic trioxide	DCC87YF	Arsenic trioxide	Clear cell renal cell carcinoma (Cell Line: A498)	[4]
Valrubicin + Plicamycin	DCPB8OE	Plicamycin	Astrocytoma (Cell Line: U251)	[4]
Valrubicin + Plicamycin	DCSMY4W	Plicamycin	Chronic myelogenous leukemia (Cell Line: K-562)	[4]
Valrubicin + Plicamycin	DCW1ARM	Plicamycin	Clear cell renal cell carcinoma (Cell Line: A498)	[4]
Valrubicin + Plicamycin	DCY1GF4	Plicamycin	Glioma (Cell Line: SF-295)	[4]
Valrubicin + Plicamycin	DCS7F2R	Plicamycin	Renal cell carcinoma (Cell Line: UO-31)	[4]
Valrubicin + Topetecan	DCRXOVT	Topetecan	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[4]
Valrubicin + Topetecan	DCJ0W9Z	Topetecan	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[4]
Valrubicin + Topetecan	DCR2ZGS	Topetecan	Anaplastic large cell lymphoma (Cell Line: SR)	[4]
Valrubicin + Topetecan	DCI4FS6	Topetecan	Astrocytoma (Cell Line: U251)	[4]
Valrubicin + Topetecan	DC691R1	Topetecan	Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)	[4]
Valrubicin + Pralatrexate	DC352PG	Pralatrexate	Clear cell renal cell carcinoma (Cell Line: TK-10)	[4]
Valrubicin + Pralatrexate	DCS6ETS	Pralatrexate	Clear cell renal cell carcinoma (Cell Line: CAKI-1)	[4]
Valrubicin + Pralatrexate	DC4FMOM	Pralatrexate	Papillary renal cell carcinoma (Cell Line: ACHN)	[4]
Valrubicin + Docetaxel	DC3TLTL	Docetaxel	Astrocytoma (Cell Line: U251)	[4]
Valrubicin + Docetaxel	DC5YD22	Docetaxel	Astrocytoma (Cell Line: SNB-19)	[4]
Valrubicin + Docetaxel	DCFI7YN	Docetaxel	Clear cell renal cell carcinoma (Cell Line: TK-10)	[4]
Valrubicin + Docetaxel	DC6P828	Docetaxel	Clear cell renal cell carcinoma (Cell Line: 786-0)	[4]
Valrubicin + Docetaxel	DCGES92	Docetaxel	Clear cell renal cell carcinoma (Cell Line: A498)	[4]
Valrubicin + Docetaxel	DCZVILY	Docetaxel	Clear cell renal cell carcinoma (Cell Line: CAKI-1)	[4]
Valrubicin + Docetaxel	DC7DHCD	Docetaxel	Glioma (Cell Line: SF-268)	[4]
Valrubicin + Docetaxel	DCEVP90	Docetaxel	Renal cell carcinoma (Cell Line: UO-31)	[4]
Valrubicin + Bendamustine hydrochloride	DC5ET3S	Bendamustine hydrochloride	Anaplastic large cell lymphoma (Cell Line: SR)	[4]
Valrubicin + Sirolimus	DCJWEPB	Sirolimus	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[4]
Valrubicin + Sirolimus	DCQF0G8	Sirolimus	Anaplastic large cell lymphoma (Cell Line: SR)	[4]
Valrubicin + Sirolimus	DCIWRID	Sirolimus	Astrocytoma (Cell Line: U251)	[4]
Valrubicin + Sirolimus	DCS9QAP	Sirolimus	Astrocytoma (Cell Line: SNB-19)	[4]
Valrubicin + Sirolimus	DC3N680	Sirolimus	Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)	[4]
Valrubicin + Sirolimus	DC3O4D8	Sirolimus	Chronic myelogenous leukemia (Cell Line: K-562)	[4]
Valrubicin + Sirolimus	DCI7BXW	Sirolimus	Clear cell renal cell carcinoma (Cell Line: TK-10)	[4]
Valrubicin + Sirolimus	DCOM3TF	Sirolimus	Clear cell renal cell carcinoma (Cell Line: CAKI-1)	[4]
Valrubicin + Sirolimus	DCKN7DO	Sirolimus	Glioblastoma (Cell Line: SNB-75)	[4]
Valrubicin + Sirolimus	DCY1J5O	Sirolimus	Glioma (Cell Line: SF-295)	[4]
Valrubicin + Sirolimus	DCSZQOU	Sirolimus	Papillary renal cell carcinoma (Cell Line: ACHN)	[4]
Valrubicin + Sirolimus	DCEICOV	Sirolimus	Plasma cell myeloma (Cell Line: RPMI-8226)	[4]
Valrubicin + Sirolimus	DC3P4R2	Sirolimus	Renal cell carcinoma (Cell Line: UO-31)	[4]
Valrubicin + Mitomycin	DCBRRDQ	Mitomycin	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[4]
Valrubicin + Mitomycin	DC00XFK	Mitomycin	Glioma (Cell Line: SF-539)	[4]
Valrubicin + Altretamine	DCBDDQV	Altretamine	Clear cell renal cell carcinoma (Cell Line: A498)	[4]
Valrubicin + Bortezomib	DCYKNJB	Bortezomib	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[4]
Valrubicin + Bortezomib	DCBDV81	Bortezomib	Anaplastic large cell lymphoma (Cell Line: SR)	[4]
Valrubicin + Bortezomib	DCE9L0Y	Bortezomib	Astrocytoma (Cell Line: U251)	[4]
Valrubicin + Bortezomib	DC6M9NP	Bortezomib	Astrocytoma (Cell Line: SNB-19)	[4]
Valrubicin + Bortezomib	DC7U5GE	Bortezomib	Clear cell renal cell carcinoma (Cell Line: 786-0)	[4]
Valrubicin + Bortezomib	DCU9JQ7	Bortezomib	Clear cell renal cell carcinoma (Cell Line: A498)	[4]
Valrubicin + Bortezomib	DC05GWW	Bortezomib	Glioma (Cell Line: SF-295)	[4]
Valrubicin + Bortezomib	DCJ40VR	Bortezomib	Glioma (Cell Line: SF-539)	[4]
Valrubicin + Bortezomib	DCRF5GE	Bortezomib	Papillary renal cell carcinoma (Cell Line: ACHN)	[4]
Valrubicin + Cisplatin	DCO0O2Y	Cisplatin	Astrocytoma (Cell Line: SNB-19)	[4]
Valrubicin + Chlorambucil	DCFPZ4K	Chlorambucil	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[4]
Valrubicin + ER819762	DCXICHQ	ER819762	Clear cell renal cell carcinoma (Cell Line: CAKI-1)	[4]
Valrubicin + ER819762	DCGLG7V	ER819762	Renal cell carcinoma (Cell Line: SN12C)	[4]
Valrubicin + Romidepsin	DCJUTXH	Romidepsin	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[4]
Valrubicin + Romidepsin	DCOTCEX	Romidepsin	Astrocytoma (Cell Line: SNB-19)	[4]
Valrubicin + Romidepsin	DCRI0Y6	Romidepsin	Glioma (Cell Line: SF-539)	[4]
Valrubicin + Romidepsin	DCEDMIP	Romidepsin	Renal cell carcinoma (Cell Line: UO-31)	[4]
Valrubicin + Romidepsin	DCDE07Y	Romidepsin	Renal cell carcinoma (Cell Line: SN12C)	[4]
Valrubicin + Azacitidine	DCLSDBU	Azacitidine	Astrocytoma (Cell Line: U251)	[4]
Valrubicin + Azacitidine	DCBECHH	Azacitidine	Clear cell renal cell carcinoma (Cell Line: CAKI-1)	[4]
Valrubicin + Azacitidine	DCAQJI9	Azacitidine	Plasma cell myeloma (Cell Line: RPMI-8226)	[4]
Valrubicin + Pomalidomide	DCV1Z5J	Pomalidomide	Clear cell renal cell carcinoma (Cell Line: TK-10)	[4]
Valrubicin + Mercaptopurine	DCE07FB	Mercaptopurine	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[4]
Valrubicin + Mercaptopurine	DC02EAY	Mercaptopurine	Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)	[4]
Valrubicin + Mercaptopurine	DCX81CX	Mercaptopurine	Astrocytoma (Cell Line: U251)	[4]
Valrubicin + Mercaptopurine	DC15RGP	Mercaptopurine	Glioblastoma (Cell Line: SNB-75)	[4]
Valrubicin + Mercaptopurine	DCADVZJ	Mercaptopurine	Plasma cell myeloma (Cell Line: RPMI-8226)	[4]
Valrubicin + PMID28870136-Compound-43	DCIMSG7	PMID28870136-Compound-43	Glioma (Cell Line: SF-268)	[4]
Valrubicin + FORMESTANE	DC8JU71	FORMESTANE	Astrocytoma (Cell Line: U251)	[4]
Valrubicin + FORMESTANE	DCBDP2O	FORMESTANE	Astrocytoma (Cell Line: SNB-19)	[4]
Valrubicin + FORMESTANE	DCWMNIP	FORMESTANE	Renal cell carcinoma (Cell Line: SN12C)	[4]
Valrubicin + Aminolevulinic Acid Hydrochloride	DCEA479	Aminolevulinic Acid Hydrochloride	Clear cell renal cell carcinoma (Cell Line: CAKI-1)	[4]
Valrubicin + Hepzato	DCIHR2J	Hepzato	Colon carcinoma (Cell Line: KM12)	[6]
Valrubicin + Ixabepilone	DCVQ11N	Ixabepilone	Colon carcinoma (Cell Line: KM12)	[6]
Valrubicin + PMID28460551-Compound-2	DCR8Y4W	PMID28460551-Compound-2	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[6]
Valrubicin + PMID28460551-Compound-2	DCQFYGI	PMID28460551-Compound-2	Carcinoma (Cell Line: RXF 393)	[6]
Valrubicin + PMID28460551-Compound-2	DCWT5M6	PMID28460551-Compound-2	Carcinoma (Cell Line: MCF7)	[6]
Valrubicin + PMID28460551-Compound-2	DCGXQ8F	PMID28460551-Compound-2	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
Valrubicin + PMID28460551-Compound-2	DCM767B	PMID28460551-Compound-2	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Valrubicin + Methotrexate	DC70L1L	Methotrexate	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Valrubicin + Arsenic trioxide	DC9538N	Arsenic trioxide	Colon adenocarcinoma (Cell Line: COLO 205)	[6]
Valrubicin + Arsenic trioxide	DCZREZV	Arsenic trioxide	Colon carcinoma (Cell Line: KM12)	[6]
Valrubicin + Plicamycin	DCCDS9D	Plicamycin	Colon adenocarcinoma (Cell Line: COLO 205)	[6]
Valrubicin + Plicamycin	DC1LPRA	Plicamycin	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Valrubicin + Topetecan	DCFEDRA	Topetecan	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Valrubicin + Pralatrexate	DCH1DQI	Pralatrexate	Colon carcinoma (Cell Line: KM12)	[6]
Valrubicin + Docetaxel	DC1T0V2	Docetaxel	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[6]
Valrubicin + Docetaxel	DC4GFQ0	Docetaxel	Carcinoma (Cell Line: RXF 393)	[6]
Valrubicin + Docetaxel	DCQ5SSA	Docetaxel	Carcinoma (Cell Line: MCF7)	[6]
Valrubicin + Docetaxel	DCRVRX4	Docetaxel	Colon carcinoma (Cell Line: KM12)	[6]
Valrubicin + Docetaxel	DCNY2DY	Docetaxel	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
Valrubicin + Docetaxel	DC89KJB	Docetaxel	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Valrubicin + Docetaxel	DCS3D6C	Docetaxel	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Valrubicin + Sirolimus	DCBG1ER	Sirolimus	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[6]
Valrubicin + Sirolimus	DCGUWQ6	Sirolimus	Carcinoma (Cell Line: RXF 393)	[6]
Valrubicin + Sirolimus	DCBI0E8	Sirolimus	Carcinoma (Cell Line: MCF7)	[6]
Valrubicin + Sirolimus	DCMSPH5	Sirolimus	Colon adenocarcinoma (Cell Line: COLO 205)	[6]
Valrubicin + Sirolimus	DC9XMNP	Sirolimus	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Valrubicin + Sirolimus	DCOHGQX	Sirolimus	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
Valrubicin + Altretamine	DCMLDUA	Altretamine	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Valrubicin + TEM	DCXAYO8	TEM	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
Valrubicin + Bortezomib	DCBRJRH	Bortezomib	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[6]
Valrubicin + Bortezomib	DC85PNM	Bortezomib	Colon carcinoma (Cell Line: KM12)	[6]
Valrubicin + Bortezomib	DC6BO7J	Bortezomib	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Valrubicin + Bortezomib	DC95D20	Bortezomib	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
Valrubicin + Romidepsin	DCEU9ID	Romidepsin	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[6]
Valrubicin + Romidepsin	DC6L0N4	Romidepsin	Carcinoma (Cell Line: MCF7)	[6]
Valrubicin + Azacitidine	DCH906O	Azacitidine	Carcinoma (Cell Line: MCF7)	[6]
Valrubicin + Azacitidine	DCNO3M0	Azacitidine	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Valrubicin + Pomalidomide	DCP6XU7	Pomalidomide	Carcinoma (Cell Line: RXF 393)	[6]
Valrubicin + Mercaptopurine	DCUU13L	Mercaptopurine	Colon adenocarcinoma (Cell Line: COLO 205)	[6]
Valrubicin + Mercaptopurine	DCE1K9D	Mercaptopurine	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Valrubicin + FORMESTANE	DCQBZDC	FORMESTANE	Carcinoma (Cell Line: RXF 393)	[6]
Valrubicin + FORMESTANE	DCPIJEX	FORMESTANE	Carcinoma (Cell Line: MCF7)	[6]
Valrubicin + Pentostatin	DCS9BPS	Pentostatin	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
Valrubicin + Pentostatin	DCYJDR4	Pentostatin	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[5]
Valrubicin + Pentostatin	DCFZ5TA	Pentostatin	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Valrubicin + Pentostatin	DC50Y2J	Pentostatin	Melanoma (Cell Line: MALME-3M)	[5]
Valrubicin + Ixabepilone	DC5K6H1	Ixabepilone	Adenocarcinoma (Cell Line: NCIH23)	[5]
Valrubicin + Ixabepilone	DCLN0OZ	Ixabepilone	Adenocarcinoma (Cell Line: HCC-2998)	[5]
Valrubicin + Ixabepilone	DCO7P2R	Ixabepilone	Adenocarcinoma (Cell Line: HT29)	[5]
Valrubicin + PMID28460551-Compound-2	DCTUY6E	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: NCIH23)	[5]
Valrubicin + PMID28460551-Compound-2	DCWC1R9	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: HCT116)	[5]
Valrubicin + PMID28460551-Compound-2	DCBXCDR	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: HCC-2998)	[5]
Valrubicin + PMID28460551-Compound-2	DCV4XC2	PMID28460551-Compound-2	Adenocarcinoma (Cell Line: HT29)	[5]
Valrubicin + PMID28460551-Compound-2	DCERJVY	PMID28460551-Compound-2	Amelanotic melanoma (Cell Line: M14)	[5]
Valrubicin + PMID28460551-Compound-2	DC2F89B	PMID28460551-Compound-2	Cutaneous melanoma (Cell Line: SK-MEL-28)	[5]
Valrubicin + PMID28460551-Compound-2	DCR02UW	PMID28460551-Compound-2	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Valrubicin + PMID28460551-Compound-2	DCAXVBH	PMID28460551-Compound-2	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Valrubicin + PMID28460551-Compound-2	DCQOMVD	PMID28460551-Compound-2	Lung adenocarcinoma (Cell Line: NCI-H522)	[5]
Valrubicin + PMID28460551-Compound-2	DCIWNBO	PMID28460551-Compound-2	Malignant melanoma (Cell Line: UACC62)	[5]
Valrubicin + PMID28460551-Compound-2	DC5ELG1	PMID28460551-Compound-2	Melanoma (Cell Line: MALME-3M)	[5]
Valrubicin + PMID28460551-Compound-2	DCBZUSG	PMID28460551-Compound-2	Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)	[5]
Valrubicin + PMID28460551-Compound-2	DC1HZBM	PMID28460551-Compound-2	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[5]
Valrubicin + PMID28460551-Compound-2	DCZNYL2	PMID28460551-Compound-2	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Valrubicin + Methotrexate	DC46UX5	Methotrexate	Adenocarcinoma (Cell Line: NCIH23)	[5]
Valrubicin + Methotrexate	DCY5MTH	Methotrexate	Adenocarcinoma (Cell Line: HCC-2998)	[5]
Valrubicin + Methotrexate	DCLFSO1	Methotrexate	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Valrubicin + Methotrexate	DCMOP29	Methotrexate	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[5]
Valrubicin + Methotrexate	DC7I1KT	Methotrexate	Melanoma (Cell Line: SK-MEL-2)	[5]
Valrubicin + Isoniazid	DC3S835	Isoniazid	Adenocarcinoma (Cell Line: HT29)	[5]
Valrubicin + Isoniazid	DCNP9JU	Isoniazid	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
Valrubicin + Isoniazid	DC6QVKX	Isoniazid	High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)	[5]
Valrubicin + Arsenic trioxide	DCGV3EZ	Arsenic trioxide	Adenocarcinoma (Cell Line: NCIH23)	[5]
Valrubicin + Arsenic trioxide	DCEYHC9	Arsenic trioxide	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[5]
Valrubicin + Plicamycin	DCSTK81	Plicamycin	Adenocarcinoma (Cell Line: A549)	[5]
Valrubicin + Plicamycin	DCGQPVA	Plicamycin	Adenocarcinoma (Cell Line: HCT116)	[5]
Valrubicin + Plicamycin	DCNDQIQ	Plicamycin	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
Valrubicin + Plicamycin	DC4I2CK	Plicamycin	Cutaneous melanoma (Cell Line: SK-MEL-28)	[5]
Valrubicin + Plicamycin	DCN27KX	Plicamycin	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[5]
Valrubicin + Plicamycin	DC6OBD5	Plicamycin	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
Valrubicin + Plicamycin	DCXPKWA	Plicamycin	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[5]
Valrubicin + Plicamycin	DCQKAVO	Plicamycin	Lung adenocarcinoma (Cell Line: NCI-H522)	[5]
Valrubicin + Plicamycin	DCQWWIG	Plicamycin	Malignant melanoma (Cell Line: UACC62)	[5]
Valrubicin + Plicamycin	DCR54V6	Plicamycin	Melanoma (Cell Line: MALME-3M)	[5]
Valrubicin + Plicamycin	DCPRQX4	Plicamycin	Melanoma (Cell Line: UACC-257)	[5]
Valrubicin + Plicamycin	DCQQIZB	Plicamycin	Melanoma (Cell Line: SK-MEL-2)	[5]
Valrubicin + Plicamycin	DCW04JH	Plicamycin	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[5]
Valrubicin + Topetecan	DCK7RJA	Topetecan	Adenocarcinoma (Cell Line: DU-145)	[5]
Valrubicin + Topetecan	DCQJ14A	Topetecan	Adenocarcinoma (Cell Line: NCIH23)	[5]
Valrubicin + Topetecan	DCM5MW2	Topetecan	Adenocarcinoma (Cell Line: A549)	[5]
Valrubicin + Topetecan	DCBKJYY	Topetecan	Adenocarcinoma (Cell Line: HCT116)	[5]
Valrubicin + Pralatrexate	DC0ZOCC	Pralatrexate	Adenocarcinoma (Cell Line: OVCAR3)	[5]
Valrubicin + Pralatrexate	DC3GAL2	Pralatrexate	Adenocarcinoma (Cell Line: NCIH23)	[5]
Valrubicin + Pralatrexate	DCD2U6I	Pralatrexate	Adenocarcinoma (Cell Line: HCC-2998)	[5]
Valrubicin + Pralatrexate	DCNJJ65	Pralatrexate	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[5]
Valrubicin + Pralatrexate	DCOHMQX	Pralatrexate	Non-small cell lung carcinoma (Cell Line: HOP-92)	[5]
Valrubicin + Pralatrexate	DC2MPRA	Pralatrexate	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Valrubicin + Ifosfamide	DC4G6IK	Ifosfamide	High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)	[5]
Valrubicin + Docetaxel	DCWQV1B	Docetaxel	Adenocarcinoma (Cell Line: DU-145)	[5]
Valrubicin + Docetaxel	DCN7UQ5	Docetaxel	Adenocarcinoma (Cell Line: A549)	[5]
Valrubicin + Docetaxel	DC1EW9E	Docetaxel	Adenocarcinoma (Cell Line: NCIH23)	[5]
Valrubicin + Docetaxel	DCVGAQS	Docetaxel	Adenocarcinoma (Cell Line: SW-620)	[5]
Valrubicin + Docetaxel	DCG5QWK	Docetaxel	Adenocarcinoma (Cell Line: HCT116)	[5]
Valrubicin + Docetaxel	DCYTFLY	Docetaxel	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
Valrubicin + Docetaxel	DCSLWUS	Docetaxel	Cutaneous melanoma (Cell Line: SK-MEL-5)	[5]
Valrubicin + Docetaxel	DCWKNLO	Docetaxel	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Valrubicin + Docetaxel	DCNO35O	Docetaxel	Lung adenocarcinoma (Cell Line: NCI-H522)	[5]
Valrubicin + Docetaxel	DCHONCJ	Docetaxel	Malignant melanoma (Cell Line: LOX IMVI)	[5]
Valrubicin + Docetaxel	DCSV7GE	Docetaxel	Malignant melanoma (Cell Line: UACC62)	[5]
Valrubicin + Docetaxel	DCGWB2J	Docetaxel	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[5]
Valrubicin + Docetaxel	DCF9D8Y	Docetaxel	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Valrubicin + Docetaxel	DC5WFCN	Docetaxel	Prostate carcinoma (Cell Line: PC-3)	[5]
Valrubicin + Bendamustine hydrochloride	DC6PF4D	Bendamustine hydrochloride	Adenocarcinoma (Cell Line: HCT-15)	[5]
Valrubicin + Bendamustine hydrochloride	DCYO7OA	Bendamustine hydrochloride	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Valrubicin + Bendamustine hydrochloride	DCNIUN0	Bendamustine hydrochloride	Melanoma (Cell Line: UACC-257)	[5]
Valrubicin + Sirolimus	DCDYF6O	Sirolimus	Adenocarcinoma (Cell Line: DU-145)	[5]
Valrubicin + Sirolimus	DCS96QI	Sirolimus	Adenocarcinoma (Cell Line: NCIH23)	[5]
Valrubicin + Sirolimus	DCA8N5T	Sirolimus	Adenocarcinoma (Cell Line: SW-620)	[5]
Valrubicin + Sirolimus	DCCCKIU	Sirolimus	Adenocarcinoma (Cell Line: HCC-2998)	[5]
Valrubicin + Sirolimus	DCJHR1L	Sirolimus	Amelanotic melanoma (Cell Line: M14)	[5]
Valrubicin + Sirolimus	DCF5UMD	Sirolimus	Cutaneous melanoma (Cell Line: SK-MEL-5)	[5]
Valrubicin + Sirolimus	DCNOQ8V	Sirolimus	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)	[5]
Valrubicin + Sirolimus	DCZFIAV	Sirolimus	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[5]
Valrubicin + Sirolimus	DCCFT8Y	Sirolimus	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[5]
Valrubicin + Sirolimus	DCIY6XO	Sirolimus	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Valrubicin + Sirolimus	DC7SH0M	Sirolimus	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Valrubicin + Sirolimus	DC2MWYO	Sirolimus	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
Valrubicin + Sirolimus	DCLHAUO	Sirolimus	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[5]
Valrubicin + Sirolimus	DCG68W3	Sirolimus	Malignant melanoma (Cell Line: UACC62)	[5]
Valrubicin + Sirolimus	DCVSLZL	Sirolimus	Melanoma (Cell Line: MALME-3M)	[5]
Valrubicin + Sirolimus	DC2QUWK	Sirolimus	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Valrubicin + Sirolimus	DC164G2	Sirolimus	Prostate carcinoma (Cell Line: PC-3)	[5]
Valrubicin + Mitomycin	DCW58RH	Mitomycin	Adenocarcinoma (Cell Line: HCC-2998)	[5]
Valrubicin + Mitomycin	DC2N1S7	Mitomycin	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[5]
Valrubicin + Altretamine	DCJKJPZ	Altretamine	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
Valrubicin + Altretamine	DC6I2AN	Altretamine	Cutaneous melanoma (Cell Line: SK-MEL-5)	[5]
Valrubicin + Altretamine	DCQ64WQ	Altretamine	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Valrubicin + Altretamine	DC4OKV4	Altretamine	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[5]
Valrubicin + TEM	DCP3OS1	TEM	Amelanotic melanoma (Cell Line: M14)	[5]
Valrubicin + TEM	DC1M76E	TEM	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[5]
Valrubicin + TEM	DCKC3O4	TEM	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
Valrubicin + TEM	DC1H6AQ	TEM	Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)	[5]
Valrubicin + TEM	DCPM4DH	TEM	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Valrubicin + TEM	DCK6V9D	TEM	Pleural epithelioid mesothelioma (Cell Line: NCI-H226)	[5]
Valrubicin + Bortezomib	DCLKRKP	Bortezomib	Adenocarcinoma (Cell Line: DU-145)	[5]
Valrubicin + Bortezomib	DC1P0TM	Bortezomib	Adenocarcinoma (Cell Line: SW-620)	[5]
Valrubicin + Bortezomib	DCZ8VF0	Bortezomib	Adenocarcinoma (Cell Line: HCC-2998)	[5]
Valrubicin + Bortezomib	DCOHIZJ	Bortezomib	Adenocarcinoma (Cell Line: HCT-15)	[5]
Valrubicin + Bortezomib	DCHCI3A	Bortezomib	Adenocarcinoma (Cell Line: HT29)	[5]
Valrubicin + Bortezomib	DCHMNKR	Bortezomib	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
Valrubicin + Bortezomib	DCWVYIA	Bortezomib	Amelanotic melanoma (Cell Line: M14)	[5]
Valrubicin + Bortezomib	DC3AL94	Bortezomib	Cutaneous melanoma (Cell Line: SK-MEL-5)	[5]
Valrubicin + Bortezomib	DCFJLST	Bortezomib	Cutaneous melanoma (Cell Line: SK-MEL-28)	[5]
Valrubicin + Bortezomib	DCGHSXL	Bortezomib	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[5]
Valrubicin + Bortezomib	DC7NKYE	Bortezomib	Lung adenocarcinoma (Cell Line: NCI-H522)	[5]
Valrubicin + Bortezomib	DCUI03M	Bortezomib	Malignant melanoma (Cell Line: LOX IMVI)	[5]
Valrubicin + Bortezomib	DCIJG5N	Bortezomib	Malignant melanoma (Cell Line: UACC62)	[5]
Valrubicin + Bortezomib	DCEZVDT	Bortezomib	Melanoma (Cell Line: UACC-257)	[5]
Valrubicin + Bortezomib	DCR8B0L	Bortezomib	Melanoma (Cell Line: MALME-3M)	[5]
Valrubicin + Cisplatin	DCKM6M8	Cisplatin	Adenocarcinoma (Cell Line: DU-145)	[5]
Valrubicin + Cisplatin	DC2RL3P	Cisplatin	Adenocarcinoma (Cell Line: A549)	[5]
Valrubicin + Cisplatin	DC2GPF1	Cisplatin	Adenocarcinoma (Cell Line: NCIH23)	[5]
Valrubicin + Cisplatin	DCCUGVG	Cisplatin	Adenocarcinoma (Cell Line: HT29)	[5]
Valrubicin + Cisplatin	DCPVUYQ	Cisplatin	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[5]
Valrubicin + Cisplatin	DCNTJ4P	Cisplatin	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[5]
Valrubicin + ER819762	DC5K2QA	ER819762	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[5]
Valrubicin + ER819762	DCNAYAP	ER819762	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Valrubicin + ER819762	DCCCEQY	ER819762	Non-small cell lung carcinoma (Cell Line: HOP-92)	[5]
Valrubicin + Romidepsin	DCNDOX1	Romidepsin	Adenocarcinoma (Cell Line: A549)	[5]
Valrubicin + Romidepsin	DC4CR6E	Romidepsin	Adenocarcinoma (Cell Line: NCIH23)	[5]
Valrubicin + Romidepsin	DCS9LBR	Romidepsin	Adenocarcinoma (Cell Line: HCT-15)	[5]
Valrubicin + Romidepsin	DCCUY18	Romidepsin	Cutaneous melanoma (Cell Line: SK-MEL-28)	[5]
Valrubicin + Romidepsin	DCVYI6K	Romidepsin	Pleural epithelioid mesothelioma (Cell Line: NCI-H226)	[5]
Valrubicin + Azacitidine	DCNF2OB	Azacitidine	Adenocarcinoma (Cell Line: NCIH23)	[5]
Valrubicin + Azacitidine	DC04PYA	Azacitidine	Adenocarcinoma (Cell Line: HT29)	[5]
Valrubicin + Azacitidine	DCSBY8V	Azacitidine	Adenocarcinoma (Cell Line: HCT116)	[5]
Valrubicin + Azacitidine	DC3VVEO	Azacitidine	Cutaneous melanoma (Cell Line: SK-MEL-5)	[5]
Valrubicin + Azacitidine	DCFEXWJ	Azacitidine	Cutaneous melanoma (Cell Line: SK-MEL-28)	[5]
Valrubicin + Azacitidine	DCLULQ6	Azacitidine	Lung adenocarcinoma (Cell Line: EKVX)	[5]
Valrubicin + Azacitidine	DCLMZR1	Azacitidine	Malignant melanoma (Cell Line: UACC62)	[5]
Valrubicin + Azacitidine	DCD9LAI	Azacitidine	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[5]
Valrubicin + Azacitidine	DCXL2RZ	Azacitidine	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Valrubicin + Azacitidine	DCEQUQ8	Azacitidine	Prostate carcinoma (Cell Line: PC-3)	[5]
Valrubicin + Mercaptopurine	DC0CP77	Mercaptopurine	Adenocarcinoma (Cell Line: HCT116)	[5]
Valrubicin + Mercaptopurine	DCS5OY9	Mercaptopurine	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[5]
Valrubicin + Mercaptopurine	DCQLUHJ	Mercaptopurine	Lung adenocarcinoma (Cell Line: NCI-H522)	[5]
Valrubicin + Mercaptopurine	DCNKDTJ	Mercaptopurine	Melanoma (Cell Line: SK-MEL-2)	[5]
Valrubicin + Mercaptopurine	DCI8R7J	Mercaptopurine	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[5]
Valrubicin + Mepacrine	DCLLJ2V	Mepacrine	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)	[5]
Valrubicin + FORMESTANE	DCBI8JR	FORMESTANE	Adenocarcinoma (Cell Line: DU-145)	[5]
Valrubicin + FORMESTANE	DCLX43N	FORMESTANE	Adenocarcinoma (Cell Line: A549)	[5]
Valrubicin + FORMESTANE	DCEDY43	FORMESTANE	Adenocarcinoma (Cell Line: HCT116)	[5]
Valrubicin + FORMESTANE	DCITBN0	FORMESTANE	Adenocarcinoma (Cell Line: HT29)	[5]
Valrubicin + FORMESTANE	DCSXK71	FORMESTANE	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[5]
Valrubicin + FORMESTANE	DC0DDIK	FORMESTANE	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Valrubicin + FORMESTANE	DC0IM15	FORMESTANE	Lung adenocarcinoma (Cell Line: MDA-MB-231)	[5]
Valrubicin + FORMESTANE	DCGI67H	FORMESTANE	Malignant melanoma (Cell Line: LOX IMVI)	[5]
Valrubicin + FORMESTANE	DCIBCYP	FORMESTANE	Melanoma (Cell Line: SK-MEL-2)	[5]
Valrubicin + FORMESTANE	DCPIC89	FORMESTANE	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[5]
Valrubicin + FORMESTANE	DCUZ8D1	FORMESTANE	Non-small cell lung carcinoma (Cell Line: HOP-92)	[5]
Valrubicin + FORMESTANE	DC3PN0D	FORMESTANE	Prostate carcinoma (Cell Line: PC-3)	[5]
Valrubicin + Aminolevulinic Acid Hydrochloride	DCMFV1O	Aminolevulinic Acid Hydrochloride	Malignant melanoma (Cell Line: LOX IMVI)	[5]
Valrubicin + Busulfan	DC8WJGM	Busulfan	Adenocarcinoma (Cell Line: HCT-15)	[5]
Vandetanib + Valrubicin	DCDU964	Vandetanib	Carcinoma (Cell Line: MCF7)	[6]
Vandetanib + Valrubicin	DCPIY83	Vandetanib	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Vandetanib + Valrubicin	DC0S521	Vandetanib	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
Vandetanib + Valrubicin	DCP7J0N	Vandetanib	Adenocarcinoma (Cell Line: A549)	[5]
Vandetanib + Valrubicin	DCM5U40	Vandetanib	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
Vandetanib + Valrubicin	DCLI4RA	Vandetanib	Amelanotic melanoma (Cell Line: M14)	[5]
Vandetanib + Valrubicin	DCPRMVI	Vandetanib	Chronic myelogenous leukemia (Cell Line: K-562)	[5]
Vandetanib + Valrubicin	DCJE0Z6	Vandetanib	Cutaneous melanoma (Cell Line: SK-MEL-28)	[5]
Vandetanib + Valrubicin	DCVB2HM	Vandetanib	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
Vandetanib + Valrubicin	DCWRBIQ	Vandetanib	Melanoma (Cell Line: SK-MEL-2)	[5]
Vandetanib + Valrubicin	DCDIA3C	Vandetanib	Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)	[5]
Vandetanib + Valrubicin	DCA0EVL	Vandetanib	Non-small cell lung carcinoma (Cell Line: HOP-92)	[5]
Vandetanib + Valrubicin	DCEM20J	Vandetanib	Plasma cell myeloma (Cell Line: RPMI-8226)	[5]
Vemurafenib + Valrubicin	DC357L4	Vemurafenib	Breast adenocarcinoma (Cell Line: MDA-MB-468)	[6]
Vemurafenib + Valrubicin	DC9DTJU	Vemurafenib	Colon adenocarcinoma (Cell Line: COLO 205)	[6]
Vemurafenib + Valrubicin	DC1MEII	Vemurafenib	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Vemurafenib + Valrubicin	DC9PF3Y	Vemurafenib	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Vemurafenib + Valrubicin	DC39B6D	Vemurafenib	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
Vemurafenib + Valrubicin	DC58HRN	Vemurafenib	Adenocarcinoma (Cell Line: HT29)	[5]
Vemurafenib + Valrubicin	DC38X64	Vemurafenib	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[5]
Vemurafenib + Valrubicin	DCMQFCW	Vemurafenib	Amelanotic melanoma (Cell Line: MDA-MB-435)	[5]
Vemurafenib + Valrubicin	DCHKPDP	Vemurafenib	Amelanotic melanoma (Cell Line: M14)	[5]
Vemurafenib + Valrubicin	DCB5B60	Vemurafenib	Anaplastic large cell lymphoma (Cell Line: SR)	[5]
Vemurafenib + Valrubicin	DCCOGH2	Vemurafenib	Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)	[5]
Vemurafenib + Valrubicin	DCTZ2YQ	Vemurafenib	Clear cell renal cell carcinoma (Cell Line: A498)	[5]
Vemurafenib + Valrubicin	DCTU84S	Vemurafenib	Clear cell renal cell carcinoma (Cell Line: TK-10)	[5]
Vemurafenib + Valrubicin	DC7I4O5	Vemurafenib	Clear cell renal cell carcinoma (Cell Line: CAKI-1)	[5]
Vemurafenib + Valrubicin	DC29OJS	Vemurafenib	Cutaneous melanoma (Cell Line: SK-MEL-5)	[5]
Vemurafenib + Valrubicin	DCE42W4	Vemurafenib	Cutaneous melanoma (Cell Line: SK-MEL-28)	[5]
Vemurafenib + Valrubicin	DC5QEY2	Vemurafenib	Glioblastoma (Cell Line: SNB-75)	[5]
Vemurafenib + Valrubicin	DCTINME	Vemurafenib	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[5]
Vemurafenib + Valrubicin	DCNUTPF	Vemurafenib	High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)	[5]
Vemurafenib + Valrubicin	DCKP6B0	Vemurafenib	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
Vemurafenib + Valrubicin	DCHVQU8	Vemurafenib	Malignant melanoma (Cell Line: LOX IMVI)	[5]
Vemurafenib + Valrubicin	DC1XRDQ	Vemurafenib	Melanoma (Cell Line: MALME-3M)	[5]
Vemurafenib + Valrubicin	DCN80NH	Vemurafenib	Melanoma (Cell Line: UACC-257)	[5]
Vemurafenib + Valrubicin	DC8KN7T	Vemurafenib	Melanoma (Cell Line: SK-MEL-2)	[5]
Vemurafenib + Valrubicin	DCB1US3	Vemurafenib	Non-small cell lung carcinoma (Cell Line: HOP-92)	[5]
Vemurafenib + Valrubicin	DCR8A84	Vemurafenib	Papillary renal cell carcinoma (Cell Line: ACHN)	[5]
Vemurafenib + Valrubicin	DCSXUYR	Vemurafenib	Plasma cell myeloma (Cell Line: RPMI-8226)	[5]
Vemurafenib + Valrubicin	DCJ45H4	Vemurafenib	Pleural epithelioid mesothelioma (Cell Line: NCI-H226)	[5]
Vemurafenib + Valrubicin	DCSUUFW	Vemurafenib	Renal cell carcinoma (Cell Line: UO-31)	[5]
Vincristine + Valrubicin	DCJH7AX	Vincristine	Adenocarcinoma (Cell Line: NCIH23)	[4]
Vincristine + Valrubicin	DC2J0T4	Vincristine	Adenocarcinoma (Cell Line: HCT-15)	[4]
Vincristine + Valrubicin	DCBJBGH	Vincristine	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[4]
Vincristine + Valrubicin	DCVZTJK	Vincristine	Anaplastic large cell lymphoma (Cell Line: SR)	[4]
Vincristine + Valrubicin	DCZIMGV	Vincristine	Clear cell renal cell carcinoma (Cell Line: 786-0)	[4]
Vincristine + Valrubicin	DC5RDFH	Vincristine	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[4]
Vincristine + Valrubicin	DCW89YX	Vincristine	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[4]
Vincristine + Valrubicin	DCPONKH	Vincristine	Prostate carcinoma (Cell Line: PC-3)	[4]
Vincristine + Valrubicin	DCQYGMV	Vincristine	Carcinoma (Cell Line: RXF 393)	[6]
Vincristine + Valrubicin	DCM5MBC	Vincristine	Invasive ductal carcinoma (Cell Line: T-47D)	[6]
Vinflunine + Valrubicin	DC2QQXS	Vinflunine	Carcinoma (Cell Line: RXF 393)	[6]
Vinflunine + Valrubicin	DC5JQA1	Vinflunine	Adenocarcinoma (Cell Line: HCT116)	[5]
Vinflunine + Valrubicin	DCGQKOX	Vinflunine	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[5]
Vinflunine + Valrubicin	DC4CQYY	Vinflunine	Lung adenocarcinoma (Cell Line: NCI-H522)	[5]
Vinflunine + Valrubicin	DCC8EFO	Vinflunine	Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)	[5]
Vinflunine + Valrubicin	DCSFPFU	Vinflunine	Prostate carcinoma (Cell Line: PC-3)	[5]
Vismodegib + Valrubicin	DCZYQB1	Vismodegib	Invasive ductal carcinoma (Cell Line: BT-549)	[6]
Vismodegib + Valrubicin	DCIK1TP	Vismodegib	Invasive ductal carcinoma (Cell Line: HS 578T)	[6]
Vismodegib + Valrubicin	DC3VA59	Vismodegib	Adenocarcinoma (Cell Line: DU-145)	[5]
Vismodegib + Valrubicin	DCBYU0Y	Vismodegib	Adult acute myeloid leukemia (Cell Line: HL-60(TB))	[5]
Vismodegib + Valrubicin	DCA8YMV	Vismodegib	Amelanotic melanoma (Cell Line: M14)	[5]
Vismodegib + Valrubicin	DCPW869	Vismodegib	Clear cell renal cell carcinoma (Cell Line: 786-0)	[5]
Vismodegib + Valrubicin	DCX6DXV	Vismodegib	Cutaneous melanoma (Cell Line: SK-MEL-28)	[5]
Vismodegib + Valrubicin	DCAWDSX	Vismodegib	Cutaneous melanoma (Cell Line: SK-MEL-5)	[5]
Vismodegib + Valrubicin	DCR0RRW	Vismodegib	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)	[5]
Vismodegib + Valrubicin	DCNUUMQ	Vismodegib	High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)	[5]
Vismodegib + Valrubicin	DCXLLZG	Vismodegib	Large cell lung carcinoma (Cell Line: NCI-H460)	[5]
Vismodegib + Valrubicin	DC098WJ	Vismodegib	Lung adenocarcinoma (Cell Line: HOP-62)	[5]
Vismodegib + Valrubicin	DCP8U6R	Vismodegib	Malignant melanoma (Cell Line: LOX IMVI)	[5]
Vismodegib + Valrubicin	DCHNJH3	Vismodegib	Melanoma (Cell Line: UACC-257)	[5]
Vismodegib + Valrubicin	DCQH126	Vismodegib	Melanoma (Cell Line: SK-MEL-2)	[5]
Vismodegib + Valrubicin	DCROUAQ	Vismodegib	Melanoma (Cell Line: MALME-3M)	[5]
Vismodegib + Valrubicin	DC4XX3L	Vismodegib	Plasma cell myeloma (Cell Line: RPMI-8226)	[5]
Vismodegib + Valrubicin	DCT3N2H	Vismodegib	Renal cell carcinoma (Cell Line: UO-31)	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 779 DrugCom(s)

References

1	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2	Valrubicin FDA Label
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
6	Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.